(Q43001756)

12 November 2017

Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment (English)

1 reference

12 November 2017

1 reference

1 reference

M Gürsoy

1

1 reference

12 November 2017

G Gür

2

1 reference

12 November 2017

H Arslan

3

1 reference

12 November 2017

N Ozdemir

4

1 reference

12 November 2017

S Boyacioglu

5

1 reference

12 November 2017

1 January 2001

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

8

1 reference

12 November 2017

1

1 reference

12 November 2017

70-77

1 reference

Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C.

12 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

A proposed system for the nomenclature of hepatitis C viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Interferon therapy for acute hepatitis C viral infection--a review by meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00268.X

10.1046/J.1365-2893.2001.00268.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference